Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & working
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of heart failure and cardiovascular diseases
3.2.1.2 Technological advancements and introduction of innovative devices
3.2.1.3 Favorable reimbursement scenario
3.2.1.4 Increasing awareness regarding heart failure treatment
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of devices
3.2.2.2 Product recalls
3.3 Growth potential analysis
3.4 Porter's analysis
3.4.1 Supplier power
3.4.2 Buyer power
3.4.3 Threat of new entrants
3.4.4 Threat of substitutes
3.4.5 Industry rivalry
3.5 PESTEL analysis
3.6 Pricing analysis, 2023
3.7 Number of heart failures at global and regional, 2023
3.8 Reimbursement scenario
3.9 Regulatory landscape
3.10 Technological landscape
3.11 Pipeline products
3.12 Future market trends
3.13 Gap analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Defibrillators
5.2.1 Implantable cardioverter defibrillators (ICDs)
5.2.1.1 Transvenous ICD
5.2.1.1.1 Single-chamber ICDs
5.2.1.1.2 Dual-chamber ICDs
5.2.1.2 Subcutaneous ICD
5.2.2 External cardioverter defibrillator
5.2.2.1 Manual external defibrillator
5.2.2.2 Automated external defibrillator
5.2.2.2.1 Semi-automated external defibrillator
5.2.2.2.2 Fully automated external defibrillator
5.2.2.3 Wearable external cardioverter defibrillator
5.3 Pacemakers
5.3.1 Implantable pacemakers
5.3.2 External pacemakers
5.4 Cardiac resynchronization therapy devices
5.4.1 Cardiac resynchronization therapy-defibrillators (CRT-D)
5.4.1.1 MRI compatible CRT-D devices
5.4.1.2 Conventional CRT-D devices
5.4.2 Cardiac resynchronization therapy-pacemakers (CRT-P)
5.4.2.1 MRI Compatible CRT-P devices
5.4.2.2 Conventional CRT-P devices
5.5 Ventricular assist devices (VADs)
5.5.1 Left ventricular assist devices (LVADs)
5.5.2 Right ventricular assist devices (RVADs)
5.5.3 Biventricular assist devices (BIVADs)
5.5.4 Percutaneous ventricular assist devices (PVADs)
5.5.5 Total artificial heart
5.6 Other products
Chapter 6 Market Estimates and Forecast, By End-use, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Hospitals
6.3 Cardiac clinics
6.4 Ambulatory surgical centers
6.5 Other end-users
Chapter 7 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 France
7.3.4 Italy
7.3.5 Spain
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 China
7.4.2 Japan
7.4.3 India
7.4.4 Australia
7.4.5 South Korea
7.4.6 Rest of Asia Pacific
7.5 Latin America
7.5.1 Brazil
7.5.2 Mexico
7.5.3 Argentina
7.5.4 Rest of Latin America
7.6 Middle East and Africa
7.6.1 Saudi Arabia
7.6.2 South Africa
7.6.3 UAE
7.6.4 Rest of Middle East and Africa
Chapter 8 Company Profiles
8.1 Abbott Laboratories
8.2 Biotronik SE & Co. KG
8.3 Boston Scientific Corporation
8.4 Koninkilijke Philips N.V.
8.5 Lepu Medical Technology Co. Ltd.
8.6 LivaNova PLC
8.7 MEDICO S.p.A.
8.8 Medtronic plc
8.9 MicroPort Scientific Corporation
8.10 OSCOR Inc.
8.11 Schiller AG
8.12 Shree Pacetronix Ltd.
8.13 St. Jude Medical, Inc.
8.14 Stryker Corporation
8.15 Terumo Corporation
